Keep reading
Blog/Investment Banking
Both structures pay the seller later in mergers and acquisitions (M&A), but they answer different questions. An earn-out is a purchase-price clause inside the acquisition agreement that pays additional consideration if the acquired business hits post-closing targets such as revenue or EBITDA. A contingent value right (CVR) is a separate right issued to target shareholders that pays if a defined event occurs, and it appears most often in public-company and life sciences deals.
The commercial difference sits in control. An earn-out usually depends on a business the buyer now runs, whereas a well-drafted CVR may turn on an external milestone such as regulatory approval. Sidley data reported by DealLawyers found that only 37 of 1,119 public deals announced between 1 January 2018 and 30 April 2023 carried a CVR, and 84% of those were life sciences transactions.
| Dimension | Earn-out | Contingent value right |
|---|---|---|
| Usual setting | Private M&A, concentrated in smaller deals | Public-company M&A, heavily life sciences |
| Legal form | Provision in the acquisition agreement | Right or instrument, usually documented in a CVR agreement alongside the merger agreement |
| Holder | Seller or selling shareholders | Target shareholders or other specified holders |
| Common trigger | Revenue, EBITDA, net income, customer retention, product or contract milestones | Regulatory approval, product launch, patent issuance, litigation outcome, asset sale, buyer share price protection |
| Risk transferred | Post-closing operating performance | Discrete event risk, sometimes buyer-stock price risk |
| Buyer influence | High where the buyer sets accounting, pricing, integration and spend | Lower for external binary milestones, but efforts covenants still matter |
| Transferability | Usually non-transferable | Varies. Most life sciences CVRs in the Sidley sample were non-transferable |
| Payout shape | Often pro rata against a formula, with caps or floors | Often all-or-nothing per milestone, commonly cash-settled in the life sciences sample |
| Dispute pressure | Metric definitions, accounting policies, operating decisions | Whether the milestone occurred, whether required efforts were used, payment mechanics |
| Securities analysis | Rarely central | May require Securities Act registration or an exemption depending on features |
Valuation gaps open when the seller prices upside that the buyer refuses to fund in cash at closing. Both tools park the disputed slice of value on the other side of a future fact, allowing the deal to sign without forcing the parties to agree on a single forecast today.
The buyer limits exposure if the forecast or pipeline disappoints, while the seller keeps a claim on outcomes it believes in. That compromise is useful, but it also shifts the disagreement from price to proof. Delaware practitioners have described earn-outs as a way to convert today’s disagreement over price into tomorrow’s litigation over the outcome.
The mechanics sit in the acquisition agreement, supported by schedules that define the metric, the measurement period and the calculation steps. The American Bar Association’s Delaware survey puts earn-outs in nearly 30% of M&A deals, with concentration in private transactions below $250 million and measurement periods commonly running one to three years.
Metrics run from revenue and EBITDA to gross profit, customer retention and non-financial milestones such as regulatory approval. The payout formula can be linear above a threshold, tiered, or a cliff that pays nothing until a target is cleared. For the underlying mechanics, see our primer on how an earn-out works in M&A and the detail on structuring payout calculations.
The weakness is structural. The seller is paid on numbers produced by a business it no longer controls, and the buyer sets integration, pricing, headcount, capex, expense allocation and accounting policy after closing.
A CVR gives holders the right to additional cash, securities or other consideration if a specified event happens inside a defined window. In plain terms, if X happens by Y date, the holder receives Z per CVR.
Two families exist. Event-driven CVRs pay on milestones such as an approval, a launch or an asset disposal. Price-protection CVRs shield target shareholders against a fall in the acquirer’s stock where the consideration is equity.
The Sidley review reported by DealLawyers found that life sciences CVRs in the sample were mostly event-driven, non-transferable and cash-settled. Treating CVRs as freely tradable instruments is therefore a drafting question, not a default.
Two further features change the workload. A rights agent or trustee may administer payments and notices, and the securities-law characterisation needs analysis because some CVRs may require registration or an available exemption depending on their terms.
The label matters less than the answer to one question: can the payer influence whether the payment becomes due?
With an earn-out, the answer is usually yes. A buyer that consolidates the sales team, shifts revenue recognition to its own policies, loads corporate overhead into the acquired entity or delays a product launch can move the measured result without breaching anything unless the agreement says otherwise. A&O Shearman’s analysis published by the Harvard Law School Forum on Corporate Governance identifies this cluster of buyer decisions as an engine of post-closing disputes.
Sellers respond with operating covenants, consistent accounting requirements, ring-fencing of the acquired business, information and audit rights and an efforts standard. Buyers resist because those covenants constrain integration and the synergy case that justified the price. That trade between operational freedom and contingent-value protection drives the negotiation, and it is covered further in our guide to negotiating earn-out provisions.
An event-driven CVR narrows the problem. An approval decision comes from a regulator, not from the buyer’s controller. Control does not disappear, though. If the buyer decides how much to spend on a trial, a filing or a launch, the efforts covenant becomes the operative clause and the dispute moves from measurement to conduct.
Contingent value is option-like. BDO’s valuation work treats it as an asymmetric payoff with a defined expiry and an uncertain trigger, valued on probability, timing, payout rule and discounting. Probability weighting is the most subjective input in the exercise.
Never carry the maximum payout as a cash equivalent in a model, a fund mark or a bid. Build four cases: zero, partial, probability-weighted base and maximum.
Assume a CVR paying $2.00 per share on a single approval milestone, 50 million shares and a two-year horizon. The assumptions are a 40% probability of approval inside the window, payment 90 days after the decision and a 12% discount rate reflecting time and the payer’s credit.
Now shift the probability to 25%. The carried value falls to roughly $19.9 million, or $0.40 per share. A single subjective input moved the mark by a third of the headline, which is why assumption changes need documenting in portfolio reviews rather than being buried in a revised model. The same discipline applies to earn-outs, where the payout is usually pro rata against an operating forecast rather than binary. Our note on earn-out valuation techniques sets out the mechanics.
Lenders and private credit teams should haircut or exclude contingent consideration entirely when sizing fixed liquidity and debt service capacity. A payment that depends on a regulator or on a disputed EBITDA schedule is not a source of certain cash.
For earn-outs, price the following before signing rather than after a missed target: the metric definition, the measurement period, the accounting policies and whether they are frozen at closing, the cap and any cliff, the buyer’s operating covenants, information and audit rights, the dispute forum and expert determination process, acceleration on a change of control, and payment security where the buyer’s credit is thin. The accounting treatment of contingent payments deserves attention early, since recognition drives the numbers the payout is measured against.
For CVRs, the list runs differently: milestone definition and any partial achievement, the outside date and expiry, settlement in cash or securities, transferability, rights agent or trustee mechanics, the efforts covenant and its standard, reporting to holders, dispute process, the securities-law analysis, and what happens if the buyer is itself acquired before the milestone. Broader context sits in our guide to contingencies in M&A.
Contingent consideration is worth what the trigger definition, the control allocation and the enforcement mechanism make it worth. A $100 million earn-out measured on an EBITDA line the buyer can reshape is worth less than a smaller CVR tied to a decision nobody at the buyer controls.
Price the clause, not the headline. If the drafting cannot survive a hostile reading by the party that has to pay, the value belongs in the upfront number or nowhere.
P.S. If deal structuring and contingent pricing are your territory, check out our Premium Resources for merger and LBO models, transaction decks and more tools to help you advance your career.
Join 80,000+ readers
One email a week: markets and finance news, the latest M&A deals and reports, investor biographies and deep dives.
Free forever. Unsubscribe anytime.
